EQUITY $ 17,307 $ 19,185
========= ======= =========
(* Represents an amount lower than $1 USD.)
NUVECTIS PHARMA, INC.
CONDENSED STATEMENTS OF OPERATIONS
(USD in thousands, except per share and share amounts)
(unaudited)
Three Months Ended Nine Months Ended September
September 30 30
-------------------------- ----------------------------
2024 2023 2024 2023
----------- ----------- ----------- -----------
OPERATING
EXPENSES:
Research and
development $ 2,819 $ 4,486 $ 8,422 $ 11,115
General and
administrative 1,540 1,672 4,976 4,916
---------- ---------- ---------- ----------
OPERATING LOSS (4,359) (6,158) (13,398) (16,031)
---------- ---------- ---------- ----------
Finance income 206 277 646 393
---------- ---------- ---------- ----------
NET LOSS $ (4,153) $ (5,881) $ (12,752) $ (15,638)
========== ========== ========== ==========
NET LOSS
ATTRIBUTABLE TO
COMMON
STOCKHOLDERS $ (4,153) $ (5,881) $ (12,752) $ (15,638)
---------- ---------- ---------- ----------
BASIC AND DILUTED
NET LOSS PER
COMMON STOCK
OUTSTANDING $ (0.24) $ (0.37) $ (0.75) $ (1.02)
========== ========== ========== ==========
Basic and diluted
weighted average
number of common
stock
outstanding 17,230,559 16,104,446 16,898,040 15,341,685
========== ========== ========== ==========
(END) Dow Jones Newswires
November 05, 2024 07:00 ET (12:00 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。